Business Description
Vaccinex Inc
NAICS : 325412
SIC : 2834
ISIN : US9186401033
Description
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.22 | |||||
| Equity-to-Asset | -0.64 | |||||
| Debt-to-Equity | -0.11 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -149.37 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 29.8 | |||||
| 3-Year EBITDA Growth Rate | 48.4 | |||||
| 3-Year EPS without NRI Growth Rate | 47.3 | |||||
| 3-Year FCF Growth Rate | 51.4 | |||||
| 3-Year Book Growth Rate | 78.2 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29 | |||||
| 9-Day RSI | 24.06 | |||||
| 14-Day RSI | 27.08 | |||||
| 6-1 Month Momentum % | -42.98 | |||||
| 12-1 Month Momentum % | -90.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.57 | |||||
| Quick Ratio | 0.57 | |||||
| Cash Ratio | 0.26 | |||||
| Days Sales Outstanding | 332.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -103.1 | |||||
| Shareholder Yield % | -158.32 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4014.91 | |||||
| Net Margin % | -3552.81 | |||||
| FCF Margin % | -3035.26 | |||||
| ROE % | -10227.78 | |||||
| ROA % | -457.22 | |||||
| ROIC % | -2037.85 | |||||
| ROC (Joel Greenblatt) % | -5020.08 | |||||
| ROCE % | -6181.62 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.07 | |||||
| EV-to-EBIT | -0.32 | |||||
| EV-to-EBITDA | -0.33 | |||||
| EV-to-Revenue | 11.54 | |||||
| EV-to-FCF | -0.38 | |||||
| Earnings Yield (Greenblatt) % | -312.5 | |||||
| FCF Yield % | -218.17 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VCNX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vaccinex Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.57 | ||
| EPS (TTM) ($) | -65.176 | ||
| Beta | 0.1 | ||
| Volatility % | 63.89 | ||
| 14-Day RSI | 27.08 | ||
| 14-Day ATR ($) | 0.588841 | ||
| 20-Day SMA ($) | 6.098675 | ||
| 12-1 Month Momentum % | -90.48 | ||
| 52-Week Range ($) | 4.432 - 100.799999 | ||
| Shares Outstanding (Mil) | 1.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vaccinex Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vaccinex Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vaccinex Inc Frequently Asked Questions
What is Vaccinex Inc(VCNX)'s stock price today?
The current price of VCNX is $5.01. The 52 week high of VCNX is $100.80 and 52 week low is $4.43.
When is next earnings date of Vaccinex Inc(VCNX)?
The next earnings date of Vaccinex Inc(VCNX) is 2024-05-15 Est..
Does Vaccinex Inc(VCNX) pay dividends? If so, how much?
Vaccinex Inc(VCNX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers